Melanoma, NRAS-mutated
Revision as of 21:22, 24 January 2019 by Warner-admin (talk | contribs) (Text replacement - " BID" to " twice per day")
| Section editor | |
|---|---|
 |
Elizabeth Buchbinder, MD Boston, MA |
Note: these are biomarker-specific regimens, please see the main melanoma page for other regimens.
2 regimens on this page
2 variants on this page
|
Advanced or metastatic disease, TKI-naive
Binimetinib monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Ascierto et al. 2013 | Phase II | ||
| Dummer et al. 2017 (NEMO) | Phase III (E) | Dacarbazine | Superior PFS |
Chemotherapy
- Binimetinib (Mektovi) 45 mg PO twice per day
Continued indefinitely
References
- Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to original article contains protocol PubMed
- NEMO: Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. link to original article contains protocol PubMed